Abstract
Inhibitors of mutated BRAF kinase together with inhibitors of MEK kinase serve as one of alternative ways in modern systemic treatment of metastatic melanoma. BRAF and MEK inhibitors also demonstrated effect in adjuvant setting.
Nevertheless, these drugs reveal a specific range of adverse reactions, skin toxicity being one of the most frequent and highly specific for certain drug combinations. The article summarizes different types of skin toxicity focused on etiopathogenetic mechanisms, grading and management.